anastrozole

(redirected from Anastrazole)
Also found in: Dictionary.
Related to Anastrazole: tamoxifen

anastrozole

 [ah-nas´trah-zōl″]
an aromatase inhibitor used for treatment of advanced breast carcinoma in postmenopausal women; it inhibits conversion of circulating androgens into estrogens.

anastrozole

Arimidex

Pharmacologic class: Nonsteroidal aromatase inhibitor

Therapeutic class: Antineoplastic

Pregnancy risk category D

Action

Reduces serum estradiol levels with no significant effect on adrenocorticoid or aldosterone level; decreases stimulating effect of estrogen on tumor growth

Availability

Tablets: 1 mg

Indications and dosages

Postmenopausal women with hormone receptor-unknown or hormone receptor-positive advanced breast cancer or with advanced breast cancer after tamoxifen therapy; adjuvant treatment for hormone receptor-positive breast cancer

Adults: 1 mg P.O. daily

Contraindications

• Hypersensitivity to drug or its components
• Women of childbearing age

Precautions

Use cautiously in:
• ischemic heart disease
• breastfeeding patients
• children (safety and efficacy not established).

Administration

• Verify that patient isn't pregnant before giving drug.

Adverse reactions

CNS: headache, weakness, dizziness, depression, paresthesia, lethargy

CV: chest pain, peripheral edema, vasodilation, hypertension, thromboembolic disease

EENT: pharyngitis

GI: nausea, vomiting, diarrhea, constipation, abdominal pain, anorexia, dry mouth

GU: vaginal bleeding, leukorrhea, vaginal dryness, pelvic pain

Musculoskeletal: decreased bone mineral density, fractures, bone or back pain, muscle weakness

Respiratory: dyspnea, cough

Skin: rash

Other: food distaste, weight gain, swelling, hot flashes, flulike symptoms, tumor flare hypersensitivity reactions (including anaphylaxis, angioedema, urticaria)

Interactions

Drug-diagnostic tests.Hepatic enzymes, low-density lipoproteins, total cholesterol: increased levels

Patient monitoring

Monitor patient closely for hypersensitivity reactions.
• Check regularly for signs and symptoms of thromboembolic disease, especially dyspnea and chest pain.
• Monitor for circulatory overload (suggested by peripheral edema, cough, and dyspnea).
• Assess for signs and symptoms of depression. Evaluate patient for suicidal ideation.
• Monitor liver function test results.

Patient teaching

Instruct patient to immediately notify prescriber if signs and symptoms of hypersensitivity occur (such as itching or swelling of face, lips, or throat).

Advise patient to immediately report signs and symptoms of thromboembolic disease and circulatory overload.
• Emphasize importance of preventing pregnancy during therapy.
• Tell patient to contact prescriber if she develops signs or symptoms of depression.
• Caution patient to avoid driving and other hazardous activities until she knows how drug affects concentration and alertness.
• Advise patient to minimize GI upset by eating small, frequent servings of food and drinking plenty of fluids.
• Inform patient that she'll undergo regular blood testing during therapy.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the tests mentioned above.

anastrozole

/anas·tro·zole/ (ah-nas´trah-zōl″) an antineoplastic used for treatment of advanced breast carcinoma in postmenopausal women.

anastrozole

a nonsteroidal aromatase inhibitor.
indication It is prescribed in the treatment of advanced breast cancer for postmenopausal women whose disease has not responded to treatment with tamoxifen.
contraindication The drug is usually effective only in patients with estrogen-dependent tumors.
adverse effects The side effects most often reported include diarrhea, fatigue, nausea, headache, hot flashes, and back pain.

anastrozole

An aromatase inhibitor, which converts androstenedione to estradiol in peripheral fat.
 
Indications
Postmenopausal women with advanced oestrogen-dependent breast cancer that does not respond to tamoxifen; unlike tamoxifen, anastrozole is not associated with increased risk of endometrial cancer.

anastrozole

An anti-oestrogen drug. Anastrozole is an aromatase-inhibitor anti-estrogen drug used in the treatment of advanced breast cancer in post-menopausal women. An aromatase is an enzyme that promotes the conversion of testosterone to the aromatic compound oestradiol (estradiol). This process occurs in women, and its inhibition can reduce oestrogen levels which can be helpful in the control of oestrogen-dependent tumours. The side effects may include any of those due to oestrogen deficiency. A brand name is Arimidex.
References in periodicals archive ?
Editor's Note: The aromatase inhibitor drug anastrazole dramatically reduces estrogen levels.
Apoptone as a single agent was also highly active compared to anastrazole and docetaxel and was similar to tamoxifen, although based on current clinical results in prostate cancer, it is expected that Apoptone would produce substantially fewer side effects or toxicities in humans than any of the other single agent therapies tested in this animal model.
By contrast, a study from the Austrian Breast and Colorectal Cancer Study Group (ABCSG) examined the role of bisphosphonates in premenopausal women treated with surgery and goserelin, and then randomly assigned to one of four treatment arms: tamoxifen, tamoxifen and ZA, anastrazole, or anastrazole and ZA.
Examples of aromatase inhibitors are anastrazole, exemestane, letrozole.
The greatest benefit was with the newest aromatase inhibitors, such as letrozole (Femara) and anastrazole (Arimidex).
Drug approval summaries: arsenic trioxide, tamoxifen citrate, anastrazole, paclitaxel, bexarotene.
Unlike tamoxifen, which works by blocking estrogen receptors on cells, the aromatase inhibitors anastrazole (Arimidex), exemestane (Aromasin) and letrozole (Femara) work by preventing androgen hormones from turning into estrogen in the first place.
A study of 94 women with breast cancer who were randomized to receive tamoxifen, anastrazole, or a combination found either tamoxifen or the combination had a detrimental effect on processing speed tasks and verbal memory (J.
However, among 1,370 women with ER+/PR- tumors, those receiving anastrazole had a 52% reduction, said Dr.
Methods: Ten male patients with a diagnosis of IHH/PE were treated with the aromatase inhibitor anastrazole (1 mg/d orally).
Q I HAVE been taking a drug for advanced breast cancer called Anastrazole for the last five years.